How would you treat a patient with metastatic NSCLC, adenocarcinoma subtype with BRAF V600K mutation, PD-L1 >50% with progression on 1st line chemo-immunotherapy?

Will treat with BRAFi/MEKi combination. We extrapolate data from experience in melanoma, given BRAF V600 mutation occurs much less commonly in NSCLC. BRAF V600K is another class I activating exon 15 BRAF mutation, which occurs in about 10% of all BRAF-mutated melanoma, and is associated with worse prognosis, with better response to immunotherapy and potentially less to BRAFi/MEKi (da Silva et al., PMID 30630828). Nonetheless, preclinically, this mutant retains sensitivity to currently available ...